Anti‐amyloid‐β treatment effects on dominantly inherited Alzheimer disease neuropathology: comparing...
Anti‐amyloid‐β treatment effects on dominantly inherited Alzheimer disease neuropathology: comparing autopsy findings with biomarker outcomes from the DIAN‐TU‐001 trial of gantenerumab or solanezumab
About this item
Full title
Author / Creator
Publisher
Hoboken: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken: John Wiley and Sons Inc
Subjects
More information
Scope and Contents
Contents
Background
Clinical trials of anti‐Aβ monoclonal antibodies in Alzheimer disease (AD) typically infer target engagement from Aβ positron emission tomography (PET) and/or cerebrospinal fluid (CSF) Aβ42/40 biomarker outcomes that measure Aβ deposits indirectly and/or incompletely. Assessment of postmortem tissue is needed to directly investigate t...
Alternative Titles
Full title
Anti‐amyloid‐β treatment effects on dominantly inherited Alzheimer disease neuropathology: comparing autopsy findings with biomarker outcomes from the DIAN‐TU‐001 trial of gantenerumab or solanezumab
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11713102
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11713102
Other Identifiers
ISSN
1552-5260
E-ISSN
1552-5279
DOI
10.1002/alz.095436
